We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Merck (MRK - Free Report) ended the recent trading session at $111.01, demonstrating a +2.54% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.53%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, lost 1%.
Shares of the pharmaceutical company witnessed a gain of 10.17% over the previous month, beating the performance of the Medical sector with its gain of 0.09%, and the S&P 500's gain of 2.06%.
The investment community will be closely monitoring the performance of Merck in its forthcoming earnings report. The company is scheduled to release its earnings on February 3, 2026. The company is expected to report EPS of $2.07, up 20.35% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $16.18 billion, reflecting a 3.56% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $8.97 per share and a revenue of $64.8 billion, demonstrating changes of +17.25% and 0%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.35% lower within the past month. Merck currently has a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Merck is currently being traded at a Forward P/E ratio of 13.64. Its industry sports an average Forward P/E of 15.3, so one might conclude that Merck is trading at a discount comparatively.
Also, we should mention that MRK has a PEG ratio of 1.17. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.57.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 216, this industry ranks in the bottom 12% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK - Free Report) ended the recent trading session at $111.01, demonstrating a +2.54% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.53%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, lost 1%.
Shares of the pharmaceutical company witnessed a gain of 10.17% over the previous month, beating the performance of the Medical sector with its gain of 0.09%, and the S&P 500's gain of 2.06%.
The investment community will be closely monitoring the performance of Merck in its forthcoming earnings report. The company is scheduled to release its earnings on February 3, 2026. The company is expected to report EPS of $2.07, up 20.35% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $16.18 billion, reflecting a 3.56% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $8.97 per share and a revenue of $64.8 billion, demonstrating changes of +17.25% and 0%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.35% lower within the past month. Merck currently has a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Merck is currently being traded at a Forward P/E ratio of 13.64. Its industry sports an average Forward P/E of 15.3, so one might conclude that Merck is trading at a discount comparatively.
Also, we should mention that MRK has a PEG ratio of 1.17. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.57.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 216, this industry ranks in the bottom 12% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.